Praesidian Capital bought a clinical and laboratory services company focused on genetic medicine, marking its first acquisition as an independent sponsor.
The genetics business specializes in the prenatal and preconception field and provides hereditary cancer-risk tests.
The private investment firm targets lower-middle-market companies in the U.S., U.K., Germany and select Northern European businesses.
